GlaxoSmithKline and Theravance announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is now available for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2-agonist (LABA). Umeclidinium exerts its effect through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. Vilanterol has shown the functional selectivity similar to salmeterol, another long-acting beta2-agonist. Anoro Ellipta is the first once-daily inhaler that combines two long-acting bronchodilators.
Anoro Ellipta is available as a 62.5mcg/25mcg strength inhaler containing 2 double-foil blister strips with 7- or 30-blisters each.
For more information call (888) 825-5249 or visit GSK.com.